Free Trial
NASDAQ:KYTX

Kyverna Therapeutics Q3 2024 Earnings Report

Kyverna Therapeutics logo
$3.24 -0.07 (-2.11%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$3.27 +0.03 (+0.80%)
As of 08/8/2025 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kyverna Therapeutics EPS Results

Actual EPS
-$0.80
Consensus EPS
-$0.81
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Kyverna Therapeutics Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kyverna Therapeutics Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Wednesday, November 13, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Kyverna Therapeutics' Q2 2025 earnings is scheduled for Monday, August 11, 2025

Kyverna Therapeutics Earnings Headlines

Kyverna Therapeutics (KYTX) to Release Quarterly Earnings on Monday
Altucher: Trump’s Great Gain is starting
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.
See More Kyverna Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kyverna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kyverna Therapeutics and other key companies, straight to your email.

About Kyverna Therapeutics

Kyverna Therapeutics (NASDAQ:KYTX), a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

View Kyverna Therapeutics Profile

More Earnings Resources from MarketBeat